Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Interferons in relapsing remitting multiple sclerosis.
BACKGROUND Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS. SEARCH STRATEGY Of 208 articles identified by a predefined ...
متن کاملThalamic neurodegeneration in relapsing-remitting multiple sclerosis.
OBJECTIVE To define the extent of neuronal injury and loss in thalamic gray matter in patients with relapsing-remitting (RR) MS and to characterize how these neuronal pathologic changes are related to disease duration. METHODS The authors studied 14 patients with RRMS (Expanded Disability Status Scale score, mean 3.25, range 2.0 to 6.0) and 14 (8 men, 6 women) age-matched healthy controls. St...
متن کاملNatalizumab in relapsing-remitting multiple sclerosis.
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease activity and reducing the risk of disability progession in RRMS, and the risk of a serious adverse event (progressive multifocal leukoencephalopathy [PML]), natalizumab was indicated in active RRMS, mostly as a sec...
متن کاملAlemtuzumab for relapsing-remitting multiple sclerosis.
In the past 10 years, the treatment options for patients with relapsing-remitting multiple sclerosis (RRMS) underwent some major changes. After relying on injectable interferon-beta preparations for quite some time, the advent of the first monoclonal antibody, natalizumab, followed by the first oral drug, fingolimod, improved the outcome of these patients and the possibilities to treat them mor...
متن کاملDimethyl fumarate for relapsing-remitting multiple sclerosis.
For many years the only drugs licensed for the treatment of multiple sclerosis (MS) were administered by injection (interferon beta, glatiramer and ▼natalizumab). Recently, three oral drugs have become available. We have previously reviewed the use of ▼fingolimod for highly active relapsing-remitting MS1 and ▼teriflunomide for the management of relapsing-remitting MS in adults.2 Here, we review...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neuroinflammation
سال: 2010
ISSN: 1742-2094
DOI: 10.1186/1742-2094-7-23